Morgan Stanley analyst Craig Hettenbach lowered the firm’s price target on HCA Healthcare (HCA) to $400 from $410 and keeps an Equal Weight rating on the shares. In “a noisy backdrop for hospital stocks,” HCA’s diversified business, solid track record and aggressive cash returns to shareholders “stand out favorably,” though greater clarity on the Health Insurance Exchange marketplace into 2026 is likely needed for multiple expansion, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $380 from $361 at TD Cowen
- HCA Healthcare price target lowered to $401 from $404 at RBC Capital
- HCA Healthcare: Hold Rating Amid Mixed Signals and Policy Uncertainty
- HCA Healthcare downgraded to Peer Perform from Outperform at Wolfe Research
- HCA Healthcare price target lowered to $390 from $416 at Barclays